Mitonafide | | MedKoo

MedKoo Cat#: 591661 | Name: Mitonafide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mitonafide inhibits the activity of M. tuberculosis NAD⁺-dependent DNA ligase A and is a DNA intercalating agent.

Chemical Structure

Mitonafide

CAS#54824-17-8

Theoretical Analysis

MedKoo Cat#: 591661

Name: Mitonafide

CAS#: 54824-17-8

Chemical Formula: C16H15N3O4

Exact Mass: 313.1063

Molecular Weight: 313.31

Elemental Analysis: C, 61.34; H, 4.83; N, 13.41; O, 20.43

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

NSC300288; NSC-300288; NSC 300288; Mitonafide

IUPAC/Chemical Name

2-(2-(dimethylamino)ethyl)-5-nitro-1H-benzo[de]isoquinoline-1,3(2H)-dione

InChi Key

XXVLKDRPHSFIIB-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H15N3O4/c1-17(2)6-7-18-15(20)12-5-3-4-10-8-11(19(22)23)9-13(14(10)12)16(18)21/h3-5,8-9H,6-7H2,1-2H3

SMILES Code

O=C1N(CCN(C)C)C(C2=CC([N+]([O-])=O)=CC3=CC=CC1=C23)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 313.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Korycka-Machala M, Nowosielski M, Kuron A, Rykowski S, Olejniczak A, Hoffmann M, Dziadek J. Naphthalimides Selectively Inhibit the Activity of Bacterial, Replicative DNA Ligases and Display Bactericidal Effects against Tubercle Bacilli. Molecules. 2017 Jan 17;22(1). pii: E154. doi: 10.3390/molecules22010154. PubMed PMID: 28106753. 2: Kumar A, Banerjee S, Roy P, Sondhi SM, Sharma A. Solvent free, catalyst free, microwave or grinding assisted synthesis of bis-cyclic imide derivatives and their evaluation for anticancer activity. Bioorg Med Chem Lett. 2017 Feb 1;27(3):501-504. doi: 10.1016/j.bmcl.2016.12.031. Epub 2016 Dec 10. PubMed PMID: 28011220. 3: Johnson CA, Hudson GA, Hardebeck LK, Jolley EA, Ren Y, Lewis M, Znosko BM. Effect of intercalator substituent and nucleotide sequence on the stability of DNA- and RNA-naphthalimide complexes. Bioorg Med Chem. 2015 Jul 1;23(13):3586-91. doi: 10.1016/j.bmc.2015.04.030. Epub 2015 Apr 17. PubMed PMID: 25960324. 4: Machado KE, de Oliveira KN, Andreossi HM, Bubniak Ldos S, de Moraes AC, Gaspar PC, Andrade Eda S, Nunes RJ, Santos-Silva MC. Apoptotic events induced by maleimides on human acute leukemia cell lines. Chem Res Toxicol. 2013 Dec 16;26(12):1904-16. doi: 10.1021/tx400284r. Epub 2013 Dec 4. PubMed PMID: 24304350. 5: Machado KE, Oliveira KN, Santos-Bubniak L, Licínio MA, Nunes RJ, Santos-Silva MC. Evaluation of apoptotic effect of cyclic imide derivatives on murine B16F10 melanoma cells. Bioorg Med Chem. 2011 Nov 1;19(21):6285-91. doi: 10.1016/j.bmc.2011.09.008. Epub 2011 Sep 10. PubMed PMID: 21964182. 6: Mukherjee A, Hazra S, Dutta S, Muthiah S, Mondhe DM, Sharma PR, Singh SK, Saxena AK, Qazi GN, Sanyal U. Antitumor efficacy and apoptotic activity of substituted chloroalkyl 1H-benz[de]isoquinoline-1,3-diones: a new class of potential antineoplastic agents. Invest New Drugs. 2011 Jun;29(3):434-42. doi: 10.1007/s10637-009-9372-z. Epub 2010 Jan 12. PubMed PMID: 20066471. 7: Tumiatti V, Milelli A, Minarini A, Micco M, Gasperi Campani A, Roncuzzi L, Baiocchi D, Marinello J, Capranico G, Zini M, Stefanelli C, Melchiorre C. Design, synthesis, and biological evaluation of substituted naphthalene imides and diimides as anticancer agent. J Med Chem. 2009 Dec 10;52(23):7873-7. doi: 10.1021/jm901131m. PubMed PMID: 19954251. 8: Mukherjee A, Dutta S, Chashoo G, Bhagat M, Saxena AK, Sanyal U. Evaluation of fluoren-NU as a novel antitumor agent. Oncol Res. 2009;17(9):387-96. PubMed PMID: 19718945. 9: Antonini I, Volpini R, Dal Ben D, Lambertucci C, Cristalli G. Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs. Bioorg Med Chem. 2008 Sep 15;16(18):8440-6. doi: 10.1016/j.bmc.2008.08.027. Epub 2008 Aug 15. PubMed PMID: 18774722. 10: Pain A, Samanta S, Dutta S, Saxena AK, Shanmugavel M, Sharma M, Qazi GN, Sanyal U. Synthesis and evaluation of ethylnitrosoureas of substituted naphthalimides as anticancer compounds. Acta Pol Pharm. 2007 Jan-Feb;64(1):27-33. PubMed PMID: 17665847. 11: Flores LV, Staples AM, Mackay H, Howard CM, Uthe PB, Sexton JS 3rd, Buchmueller KL, Wilson WD, O'Hare C, Kluza J, Hochhauser D, Hartley JA, Lee M. Synthesis and evaluation of an intercalator-polyamide hairpin designed to target the inverted CCAAT box 2 in the topoisomerase IIalpha promoter. Chembiochem. 2006 Nov;7(11):1722-9. PubMed PMID: 16991167. 12: Samanta S, Pain A, Dutta S, Saxena AK, Shanmugavel M, Pandita RM, Qazi GN, Sanyal U. Antitumor activity of Nitronaphthal-NU, a novel mixed-function agent. J Exp Ther Oncol. 2005;5(1):15-22. PubMed PMID: 16416597. 13: Pain A, Samanta S, Dutta S, Saxena AK, Shanmugavel M, Kampasi H, Qazi GN, Sanyal U. Evaluation of naphthalmustine, a nitrogen mustard derivative of naphthalimide as a rationally-designed anticancer agent. J Exp Clin Cancer Res. 2003 Sep;22(3):411-8. PubMed PMID: 14582700. 14: Braña MF, Ramos A. Naphthalimides as anti-cancer agents: synthesis and biological activity. Curr Med Chem Anticancer Agents. 2001 Nov;1(3):237-55. Review. PubMed PMID: 12678756. 15: Gil-Alegre ME, Bernabeu JA, Camacho MA, Torres-Suarez AI. Statistical evaluation for stability studies under stress storage conditions. Farmaco. 2001 Nov;56(11):877-83. PubMed PMID: 11765040. 16: Spicer JA, Gamage SA, Atwell GJ, Finlay GJ, Baguley BC, Denny WA. Dimeric analogues of non-cationic tricyclic aromatic carboxamides are a new class of cytotoxic agents. Anticancer Drug Des. 1999 Jun;14(3):281-9. PubMed PMID: 10500503. 17: Ghaneolhosseini H, Sjöberg S. Synthesis of a boronated naphthalimide for potential use in boron neutron capture therapy (BNCT). Acta Chem Scand. 1999 Apr;53(4):298-300. PubMed PMID: 10214688. 18: Slunt KM, Grace JM, Macdonald TL, Pearson RD. Effect of mitonafide analogs on topoisomerase II of Leishmania chagasi. Antimicrob Agents Chemother. 1996 Mar;40(3):706-9. PubMed PMID: 8851597; PubMed Central PMCID: PMC163184. 19: Casado A, Rosell R, García-Gómez R, Díaz-Rubio E, Pérez-Manga G, Font A, Benavides A, Martín M. Phase II study of mitonafide in non-small cell lung cancer (NSCLC). Invest New Drugs. 1996;14(4):415-7. PubMed PMID: 9157079. 20: Abad A, Grávalos C, Font A, Molina F, Díaz-Puente MT, Fabregat X, Benavides A, Martín M. Phase II study of Mitonafide in advanced and relapsed colorectal cancer. Invest New Drugs. 1996;14(2):223-5. PubMed PMID: 8913845.